Kezhong Chen1, Jing Bai2, Alexandre Reuben3, Heng Zhao1, Guannan Kang1, Chunliu Zhang2, Qingyi Qi4, Yaping Xu2, Shawna Hubert3,5, Lianpeng Chang2, Yanfang Guan2,6, Lin Feng7, Kai Zhang8, Kaitai Zhang7, Xin Yi2,6, Xuefeng Xia2, Shujun Cheng7, Fan Yang1, Jianjun Zhang3,5, Jun Wang1. 1. Department of Thoracic Surgery and. 2. Geneplus-Beijing Institute, Beijing China. 3. Department of Thoracic/Head and Neck Medical Oncology and. 4. Department of Radiology, Peking University People's Hospital, China. 5. Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. 6. Department of Computer Science and Technology, School of Electronic and Information Engineering, Xi'an Jiaotong University, Xi'an, China; and. 7. State Key Laboratory of Molecular Oncology, Department of Etiology and Carcinogenesis, Cancer Institute and Hospital, and. 8. Department of Cancer Prevention, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
Abstract
Rationale: Ground-glass opacity (GGO)-associated lung cancers are common and radiologically distinct clinical entities known to have an indolent clinical course and superior survival, implying a unique underlying biology. However, the molecular and immune characteristics of GGO-associated lung nodules have not been systemically studied. Objectives: To provide mechanistic insights for the treatment of these radiologically distinct clinical entities. Methods: We initiated a prospective cohort study to collect and characterize pulmonary nodules with GGO components (nonsolid and part-solid nodules) or without GGO components, as precisely quantified by using three-dimensional image reconstruction to delineate the molecular and immune features associated with GGO. Multiomics assessment conducted by using targeted gene panel sequencing, RNA sequencing, TCR (T-cell receptor) sequencing, and circulating tumor DNA detection was performed. Measurements and Main Results: GGO-associated lung cancers exhibited a lower tumor mutation burden than solid nodules. Transcriptomic analysis revealed a less active immune environment in GGO components and immune pathways, decreased expression of immune activation markers, and less infiltration of most immune-cell subsets, which was confirmed by using multiplex immunofluorescence. Furthermore, T-cell repertoire sequencing revealed lower T-cell expansion in GGO-associated lung cancers. HLA loss of heterozygosity was significantly less common in lung adenocarcinomas with GGO components than in those without. Circulating tumor DNA analysis suggested that the release of tumor DNA to the peripheral blood was correlated with the tumor size of non-GGO components. Conclusions: Compared with lung cancers presenting with solid lung nodules, GGO-associated lung cancers are characterized by a less active metabolism and a less active immune microenvironment, which may be the mechanisms underlying their indolent clinical course. Clinical trial registered with www.clinicaltrials.gov (NCT03320044).
Rationale: Ground-glass opacity (GGO)-associated lung cancers are common and radiologically distinct clinical entities known to have an indolent clinical course and superior survival, implying a unique underlying biology. However, the molecular and immune characteristics of GGO-associated lung nodules have not been systemically studied. Objectives: To provide mechanistic insights for the treatment of these radiologically distinct clinical entities. Methods: We initiated a prospective cohort study to collect and characterize pulmonary nodules with GGO components (nonsolid and part-solid nodules) or without GGO components, as precisely quantified by using three-dimensional image reconstruction to delineate the molecular and immune features associated with GGO. Multiomics assessment conducted by using targeted gene panel sequencing, RNA sequencing, TCR (T-cell receptor) sequencing, and circulating tumor DNA detection was performed. Measurements and Main Results: GGO-associated lung cancers exhibited a lower tumor mutation burden than solid nodules. Transcriptomic analysis revealed a less active immune environment in GGO components and immune pathways, decreased expression of immune activation markers, and less infiltration of most immune-cell subsets, which was confirmed by using multiplex immunofluorescence. Furthermore, T-cell repertoire sequencing revealed lower T-cell expansion in GGO-associated lung cancers. HLA loss of heterozygosity was significantly less common in lung adenocarcinomas with GGO components than in those without. Circulating tumor DNA analysis suggested that the release of tumor DNA to the peripheral blood was correlated with the tumor size of non-GGO components. Conclusions: Compared with lung cancers presenting with solid lung nodules, GGO-associated lung cancers are characterized by a less active metabolism and a less active immune microenvironment, which may be the mechanisms underlying their indolent clinical course. Clinical trial registered with www.clinicaltrials.gov (NCT03320044).
Authors: Marcelo V Negrao; Vincent K Lam; Alexandre Reuben; Maria Laura Rubin; Lara Lacerda Landry; Emily B Roarty; Waree Rinsurongkawong; Jeff Lewis; Jack A Roth; Stephen G Swisher; Don L Gibbons; Ignacio I Wistuba; Vassiliki Papadimitrakopoulou; Bonnie S Glisson; George R Blumenschein; J Jack Lee; John V Heymach; Jianjun Zhang Journal: J Thorac Oncol Date: 2019-02-16 Impact factor: 15.609
Authors: Kroopa Joshi; Marc Robert de Massy; Mazlina Ismail; James L Reading; Imran Uddin; Annemarie Woolston; Emine Hatipoglu; Theres Oakes; Rachel Rosenthal; Thomas Peacock; Tahel Ronel; Mahdad Noursadeghi; Virginia Turati; Andrew J S Furness; Andrew Georgiou; Yien Ning Sophia Wong; Assma Ben Aissa; Mariana Werner Sunderland; Mariam Jamal-Hanjani; Selvaraju Veeriah; Nicolai J Birkbak; Gareth A Wilson; Crispin T Hiley; Ehsan Ghorani; José Afonso Guerra-Assunção; Javier Herrero; Tariq Enver; Sine R Hadrup; Allan Hackshaw; Karl S Peggs; Nicholas McGranahan; Charles Swanton; Sergio A Quezada; Benny Chain Journal: Nat Med Date: 2019-10-07 Impact factor: 53.440
Authors: Hitoshi Dejima; Xin Hu; Runzhe Chen; Jiexin Zhang; Junya Fujimoto; Edwin R Parra; Cara Haymaker; Shawna M Hubert; Dzifa Duose; Luisa M Solis; Dan Su; Junya Fukuoka; Kazuhiro Tabata; Hoa H N Pham; Nicholas Mcgranahan; Baili Zhang; Jie Ye; Lisha Ying; Latasha Little; Curtis Gumbs; Chi-Wan Chow; Marcos Roberto Estecio; Myrna C B Godoy; Mara B Antonoff; Boris Sepesi; Harvey I Pass; Carmen Behrens; Jianhua Zhang; Ara A Vaporciyan; John V Heymach; Paul Scheet; J Jack Lee; Jia Wu; P Andrew Futreal; Alexandre Reuben; Humam Kadara; Ignacio I Wistuba; Jianjun Zhang Journal: Nat Commun Date: 2021-05-11 Impact factor: 14.919
Authors: Xin Hu; Marcos R Estecio; Runzhe Chen; Alexandre Reuben; Linghua Wang; Junya Fujimoto; Jian Carrot-Zhang; Nicholas McGranahan; Lisha Ying; Junya Fukuoka; Chi-Wan Chow; Hoa H N Pham; Myrna C B Godoy; Brett W Carter; Carmen Behrens; Jianhua Zhang; Mara B Antonoff; Boris Sepesi; Yue Lu; Harvey I Pass; Humam Kadara; Paul Scheet; Ara A Vaporciyan; John V Heymach; Ignacio I Wistuba; J Jack Lee; P Andrew Futreal; Dan Su; Jean-Pierre J Issa; Jianjun Zhang Journal: Nat Commun Date: 2021-01-29 Impact factor: 14.919
Authors: Dong Woog Yoon; Chu Hyun Kim; Soohyun Hwang; Yoon-La Choi; Jong Ho Cho; Hong Kwan Kim; Yong Soo Choi; Jhingook Kim; Young Mog Shim; Sumin Shin; Ho Yun Lee Journal: Insights Imaging Date: 2022-06-17